<DOC>
	<DOCNO>NCT03029351</DOCNO>
	<brief_summary>This prospective study evaluate effect Exenatide extend release treatment 1 year albuminuria level T2DM patient micro- macroalbuminuria compare placebo .</brief_summary>
	<brief_title>GLP-1 Receptor Agonist Therapy Albuminuria Patients With Type 2 Diabetes</brief_title>
	<detailed_description>This prospective study evaluate effect Exenatide extend release treatment 1 year albuminuria level T2DM patient micro- macroalbuminuria compare placebo . The similarity baseline value study group compare use appropriate parametric test . Transformations data order meet statistical assumption may consider . All statistical analysis carry use SPSS software ( SPSS Inc , Chicago , Illinois ) base intention treat principle . Data present mean±standard error . The primary endpoint study change baseline albuminuria level week 12 , 26 , 39 56 follow Exenatide extend release placebo treatment . Fasting sample collect week 0 , 12 , 26 , 39 56 used assessment value week 0 consider baseline . Changes baseline form drug arm compare placebo arm micro macroalbuminuria group . The statistical analysis do use mixed model repeat measurement ( MMRM ) analysis assign α value 0.05 . Our preliminary data retrospective analysis difference albuminuria follow GLP-1RA treatment 2.5 yr T2DM patient micro macroalbuminuria show regression albuminuria ( UACR ) approximately 55mg/mg 500mg/g ( 50 % reduction ) , respectively . Conservatively estimate difference change baseline albuminuria 1 year Exenatide extend release placebo group ( across albuminuria group ) 60mg/g , standard deviation 91mg/g , sample size 38 patient per group provide adequate power ( beta = 0.2 ) detect significant difference ( alpha = 0.05 ) . Assuming drop-out rate 15 % 2:1 drug : placebo randomization ratio , 60 active 30 control recruit total 90 patient ( round ) . Patients enrol base predetermine stratification accord two albuminuria category ( micro macro 1:1 ratio ) 45 patient . The secondary end point include comparison change albuminuria base baseline albuminuria category ( micro macro ) , creatinine clearance , Cystatin C , TGFβ , type I IV collagen , CTGF , fibronectin level , expression SMAD3 , SMAD4 , NQO-1 , GST-1P HO-1 , Nrf-2/keap-1 system activation Exenatide extend release placebo group across albuminuria category</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Type 2 Diabetes least 1 year . Microalbuminuria least 6 month ( UACR : 30300 mg/g ) Macroalbuminuria least 6 month ( UACR : &gt; 300 mg/g ) HbA1c ≤10 % Ages 1865 year ( inclusive age 18 65 ) On ARBs/ACEi &gt; 3months Use GLP1 Receptor agonists SGLT2 inhibitor therapy last 3 month History risk pancreatitis ( e.g. , history gallstone , alcohol abuse , hypertriglyceridemia ) Coronary event procedure ( myocardial infarction , unstable angina , coronary artery bypass , surgery coronary angioplasty ) previous 3 month Hepatic disease : Severe hepatic insufficiency and/or significant abnormal liver function define : 1 . Aspartate aminotransferase ( AST ) &gt; 3x upper limit normal ( ULN ) and/or alanine aminotransferase ( ALT ) &gt; 3x ULN 2 . Total bilirubin &gt; 2.0 mg/dL ( 34.2 µmol/L ) 3 . Positive serologic evidence current infectious liver disease include Hepatitis B viral antibody IGM , Hepatitis B surface antigen Hepatitis C virus antibody 4 . Liver function test 3 time upper limit normal Renal impairment ( serum eGFR &lt; 30 ml/min ) HIV Inability give informed consent History gastroparesis History medullary thyroid carcinoma MEN 2 syndrome Alcoholism Hypertriglyceridemia ( &gt; 500 mg/dl ) . Any lifethreatening , noncardiac disease Uncontrolled hypertension ( BP &gt; 160/100 mm Hg ) Congestive Heart Failure class III IV Use investigational agent therapeutic regimen within 30 day study Participation concurrent clinical trial Pregnant breastfeeding patient females childbearing age 2 form acceptable contraceptive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>albuminuria</keyword>
	<keyword>GLP-1 Receptor Agonist</keyword>
	<keyword>Type 2 Diabetes</keyword>
</DOC>